STADA: Annual General Meeting approves agenda items with a large majority

Bad Vilbel, June 6, 2018 - STADA Arzneimittel AG announced today that the Company's shareholders approved all agenda items with a large majority that were put to a vote by the Executive Board and the Supervisory Board at the Annual General Meeting held on June 6, 2018 in Frankfurt/Main.

73.5 percent of the voting share capital were represented at the 2018 Annual General Meeting.

Further details of the Annual General Meeting, including the voting results for each item on the agenda, are available on the STADA website at www.stada.com/agm2018.

About STADA Arzneimittel AG

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2017, STADA achieved adjusted Group sales of Euro 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 433.9 million and adjusted net income of Euro 195.6 million. As of December 31, 2017, STADA employed 10,176 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel - Germany /Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de